
In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.











In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.

Moshe Prero, MD, says bronchopulmonary dysplasia remains relevant into adulthood and details home safety priorities for children with tracheostomies.

Nathan explains why a TETON-2 post hoc analysis of recurrent events, 126 vs 161 with placebo, supports continuing inhaled treprostinil after progression.

Rohit Gupta, MD, discusses advanced pulmonary sarcoidosis, antifibrotic uncertainty, and first-line methotrexate data after a CHEST 2026 session.

James Chalmers, MBChB, PhD, discusses an ASPEN post hoc analysis linking sputum color to neutrophil serine protease activity at CHEST 2026.

Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.

Patients with IPF reported less severe, less frequent cough within 2 weeks of nalbuphine ER in CORAL, with gains sustained through week 6.

Michael Pritchett, DO, MPH, discusses real-world Ion Registry yield, sensitivity, and safety data for robotic bronchoscopy presented at CHEST 2026.

Moshe Prero, MD, says gene therapy has changed respiratory care in SMA type 1, but residual sleep, swallowing, and spinal issues still warrant monitoring.

In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.

Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.

Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.

Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.